Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours

European Journal of Cancer

Volumn 46, Issue 4, 2010, Pages 729-734

  Isambert, N ^a,b   Campone, M ^c   Bourbouloux, E ^c   Drouin, M ^d   Major, A ^d   Yin, W ^d   Loadman, P ^e   Capizzi, R ^d   Grieshaber, C ^d   Fumoleau, P ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d Antisoma Research Limited   (United States)

^e UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

C 1311; Imidazoacridinone; Pharmacokinetics; Phase I study

Indexed keywords

IMIDACRINE; SYMADEX; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; LIVER FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 76049126982     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.005     Document Type: Article

References (14)

1. Calabrese C.R., Loadman P.M., Lim L.S., et al. In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans. Drug Metab Dispos 27 2 (1999 Feb) 240-245
2. Cholody W.M., Martelli S., and Konopa J. 8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity. J Med Chem 33 10 (1990) 2852-2856
3. Calabrese C.R., Bibby M.C., Double J.A., and Loadman P.M. Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice. Cancer Chemother Pharmacol 42 5 (1998) 379-385
4. Dziegielewski J., Slusarski B., Konitz A., Skladanowski A., and Konopa J. Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem Pharmacol 63 9 (2002) 1653-1662
5. Mazerska Z., Dziegielewski J., and Konopa J. Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA. Biochem Pharmacol 61 6 (2001) 685-694
6. Augustin E., Wheatley D.N., Lamb J., and Konopa J. Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cells. Cancer Chemother Pharmacol 38 1 (1996) 39-44
7. Burger A.M., Double J.A., Konopa J., and Bibby M.C. Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Brit J Cancer 74 9 (1996 Nov) 1369-1374
8. Mazerska Z., Augustin E., Skladanowski A., Bibby M., Double J., and konopa J. C-1311. Drug of the Future 23 7 (1998) 702-706
9. Berger B., Marquardt H., and Westendorf J. Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Cancer Res 56 9 (1996) 2094-2104
10. Skladanowski A, Come M, Laurent G, konopa J, Larsen A. PSC-833 and tubulin interacting agents reverse the altered drug distribution in multidrug resistant HL-60 cells as revealed by the fluorescent antitumor drug imidacrine. In: Proc Amer assoc cancer res, vol. 38; 1997.
11. Warr J., Quinn D., Double J., and Bibby M. Low level multidrug resistance expression to C1311, a potential clinical candidate. Brit J Cancer 75 (1997) 33
12. Skladanowski A., Plisov S.Y., Konopa J., and Larsen A.K. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 49 5 (1996) 772-780
13. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
14. Lamb J., and Wheatley D.N. Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation. Brit J Cancer 74 9 (1996) 1359-1368